Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target genomic loci with partial complementarity to the G6PC guide RNA are unintended DNA sequences that share significant sequence homology with the target site in the Glucose-6-Phosphatase Catalytic Subunit (G6PC) gene (Chou et al., 2018, Nature Reviews Endocrinology). In CRISPR-Cas9 based therapies for Glycogen Storage Disease Type Ia (GSDIa), the guide RNA (gRNA) is designed to direct the Cas9 nuclease to the G6PC locus; however, the enzyme may also bind and cleave these off-target sites due to partial complementarity (Zhang et al., 2015, Science). Such unintended cleavage can lead to permanent mutations, including insertions and deletions (indels) or large-scale chromosomal rearrangements, which may disrupt essential genes or regulatory elements (Fu et al., 2013, Nature Biotechnology). These events pose a substantial safety risk, potentially leading to cellular transformation or loss of function in non-target pathways. Consequently, the identification and characterization of these loci using methods like GUIDE-seq or CIRCLE-seq are mandatory steps in the preclinical evaluation of G6PC-targeting gene editors (Tsai et al., 2015, Nature Biotechnology). Minimizing activity at these loci is a primary goal in the development of high-fidelity Cas9 variants and optimized gRNA architectures for treating metabolic disorders.
Unintended double-strand breaks (DSBs) followed by error-prone DNA repair mechanisms such as non-homologous end joining (NHEJ) or homology-directed repair (HDR) at non-target genomic sites (Fu et al., 2013, Nature Biotechnology).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target genomic loci with partial complementarity to the G6PC guide RNA (G6PC off-target sites).